Eli Lilly and Company
LLY
NYSE·Healthcare·Drug Manufacturers - General·Mkt cap $1.1T
$1,148.20
▼ -0.98%
P/E
38.52
Mkt Cap
$1.1T
52-Wk Range
$712.05–$1,293
52-Week Range
$712.05 - $1,292.65
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 55.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Diversified therapeutic portfolio reducing revenue concentration risk
- Strong patent protection and extensive drug pipeline for future growth
- Global manufacturing and distribution infrastructure with established market access
- Significant R&D investment capabilities and clinical trial expertise
- Brand recognition and physician trust across multiple therapeutic categories
Bear Case
2 risks
- Low volatility (beta 0.5).
- Growth premium of 2.5x vs Large Cap Pharma peers. Elevated but may be justified by growth trajectory.
Growth
Moderate growth ahead
Rising global diabetes prevalence driving demand for insulin and GLP-1 therapies
Value
Growth premium of 2.5x vs Large Cap Pharma peers. Elevated but may be justified by growth trajectory.
Momentum
Stable
+1.5% over 3m
Quality
Excellent
High-growth business (50% revenue growth, 84% gross margin). Profitable with strong growth momentum.
Dividend
Modest
0.58% yield
Smart-money signal
Who's buying LLY right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 29, 2026
AUG 5, 2026
Reported EPS of $8.38 vs $6.40 consensus (+30.9% surprise). Revenue of $23.0B vs $20.8B expected (+10.3%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+30.9%
Revenue trend · last 8Q
—
+45%
+45%
+38%
+54%
+43%
+56%
+48%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$11.4B
$13.5B
$12.7B
$15.6B
$17.6B
$19.3B
$19.8B
$23.0B
Margins · last 8Q
Gross
85.8%
Operating
39.1%
Profit
30.9%
Wall Street consensus
13 analysts · 92% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
92%
Hold
0%
Sell
8%
Median Price Target
—
Latest: BMO Capital · Sep 1, 2026
vs Industry
How LLY stacks vs Drug Manufacturers - General
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related